Aviva
CPRX

Aviva’s Catalyst Pharmaceutical CPRX Stock Holding History

Aviva’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$440K Sell
14,000
-4,963
-26% -$146K ﹤0.01% 773
2026
Q1 		$470K Sell
18,963
-2,033
-10% -$48.4K ﹤0.01% 707
2025
Q4 		$490K Sell
20,996
-3,129
-13% -$69.7K ﹤0.01% 775
2025
Q3 		$475K Buy
24,125
+4,557
+23% +$93.7K ﹤0.01% 778
2025
Q2 		$425K Sell
19,568
-7,868
-29% -$186K ﹤0.01% 845
2025
Q1 		$665K Sell
27,436
-724
-3% -$16.3K ﹤0.01% 649
2024
Q4 		$588K Sell
28,160
-3,719
-12% -$79.9K ﹤0.01% 715
2024
Q3 		$634K Sell
31,879
-7,303
-19% -$135K ﹤0.01% 770
2024
Q2 		$607K Sell
39,182
-1,975
-5% -$30.7K ﹤0.01% 771
2024
Q1 		$656K Sell
41,157
-1,977
-5% -$29.8K ﹤0.01% 765
2023
Q4 		$725K Buy
+43,134
New +$590K ﹤0.01% 725
2022
Q1 		– Sell
-386,085
Closed -$2.61M – 1070
2021
Q4 		$2.61M Buy
386,085
+59,700
+18% +$393K 0.01% 769
2021
Q3 		$1.73M Buy
+326,385
New +$1.78M 0.01% 787

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Aviva's CPRX Position: Q2 2026 in Review

Aviva reduced its Catalyst Pharmaceutical (CPRX) stake by 26% in Q2 2026, selling an estimated $146K and leaving 14,000 shares worth $440K. The position accounts for ﹤0.01% of the portfolio, ranked #773.

Aviva first reported a position in CPRX in Q3 2021 and has held it in 13 quarters since. The position peaked at $2.61M in Q4 2021. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Aviva held 14,000 shares of Catalyst Pharmaceutical worth $440K as of Q2 2026.
  • Aviva sold 4,963 Catalyst Pharmaceutical shares in Q2 2026, an estimated $146K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Aviva's portfolio in Q2 2026, its #773 holding.
  • Aviva first reported a position in Catalyst Pharmaceutical in Q3 2021 and has held it in 13 quarters since.
  • Aviva's Catalyst Pharmaceutical position peaked at $2.61M in Q4 2021.
  • 395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.